Vivet Therapeutics y Pfizer Inc reciben autorización de la FDA para iniciar GATEWAY, ensayo clínico de fase 1/2 con VTX-801, la terapia génica de Vivet para la enfermedad de Wilson

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement